Biocept

BIOC NASDAQ
1.240
+0.110
+9.73%
After Hours: 1.300 +0.06 +4.84% 18:59 05/24 EDT
Open
1.210
Prev Close
1.130
High
1.480
Low
1.160
Volume
11.52M
Avg Vol (3M)
4.11M
52 Week High
12.15
52 Week Low
0.6580
% Turnover
61.06%
Market Cap
23.40M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
MORE >

Recently

Name
Price
%Change